The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer
Pancreatic ductal adenocarcinoma cancer (PDAC) is projected to become the second leading cause of cancer-related death in the United States by 2030. Patients are often diagnosed with advanced disease, which explains the dismal 5-year median overall survival rate of ~12%. Immunotherapy has been succe...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/24/5708 |
| _version_ | 1797381763133079552 |
|---|---|
| author | Sherise Rogers Angel Charles Ryan M. Thomas |
| author_facet | Sherise Rogers Angel Charles Ryan M. Thomas |
| author_sort | Sherise Rogers |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma cancer (PDAC) is projected to become the second leading cause of cancer-related death in the United States by 2030. Patients are often diagnosed with advanced disease, which explains the dismal 5-year median overall survival rate of ~12%. Immunotherapy has been successful in improving outcomes in the past decade for a variety of malignancies, including gastrointestinal cancers. However, PDAC is historically an immunologically “cold” tumor, one with an immunosuppressive environment and with restricted entry of immune cells that have limited the success of immunotherapy in these tumors. The microbiome, the intricate community of microorganisms present on and within humans, has been shown to contribute to many cancers, including PDAC. Recently, its role in tumor immunology and response to immunotherapy has generated much interest. Herein, the current state of the interaction of the microbiome and immunotherapy in PDAC is discussed with a focus on needed areas of study in order to harness the immune system to combat pancreatic cancer. |
| first_indexed | 2024-03-08T20:56:10Z |
| format | Article |
| id | doaj.art-e3b9e694a5fa4252a11e603524d8495a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T20:56:10Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e3b9e694a5fa4252a11e603524d8495a2023-12-22T13:58:37ZengMDPI AGCancers2072-66942023-12-011524570810.3390/cancers15245708The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic CancerSherise Rogers0Angel Charles1Ryan M. Thomas2Department of Medicine, Division of Hematology and Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USADepartment of Surgery, University of Florida College of Medicine, Gainesville, FL 32610, USADepartment of Surgery, University of Florida College of Medicine, Gainesville, FL 32610, USAPancreatic ductal adenocarcinoma cancer (PDAC) is projected to become the second leading cause of cancer-related death in the United States by 2030. Patients are often diagnosed with advanced disease, which explains the dismal 5-year median overall survival rate of ~12%. Immunotherapy has been successful in improving outcomes in the past decade for a variety of malignancies, including gastrointestinal cancers. However, PDAC is historically an immunologically “cold” tumor, one with an immunosuppressive environment and with restricted entry of immune cells that have limited the success of immunotherapy in these tumors. The microbiome, the intricate community of microorganisms present on and within humans, has been shown to contribute to many cancers, including PDAC. Recently, its role in tumor immunology and response to immunotherapy has generated much interest. Herein, the current state of the interaction of the microbiome and immunotherapy in PDAC is discussed with a focus on needed areas of study in order to harness the immune system to combat pancreatic cancer.https://www.mdpi.com/2072-6694/15/24/5708pancreatic cancerpancreatic ductal adenocarcinomamicrobiomemicrobiotaimmunotherapy |
| spellingShingle | Sherise Rogers Angel Charles Ryan M. Thomas The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer Cancers pancreatic cancer pancreatic ductal adenocarcinoma microbiome microbiota immunotherapy |
| title | The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer |
| title_full | The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer |
| title_fullStr | The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer |
| title_full_unstemmed | The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer |
| title_short | The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer |
| title_sort | prospect of harnessing the microbiome to improve immunotherapeutic response in pancreatic cancer |
| topic | pancreatic cancer pancreatic ductal adenocarcinoma microbiome microbiota immunotherapy |
| url | https://www.mdpi.com/2072-6694/15/24/5708 |
| work_keys_str_mv | AT sheriserogers theprospectofharnessingthemicrobiometoimproveimmunotherapeuticresponseinpancreaticcancer AT angelcharles theprospectofharnessingthemicrobiometoimproveimmunotherapeuticresponseinpancreaticcancer AT ryanmthomas theprospectofharnessingthemicrobiometoimproveimmunotherapeuticresponseinpancreaticcancer AT sheriserogers prospectofharnessingthemicrobiometoimproveimmunotherapeuticresponseinpancreaticcancer AT angelcharles prospectofharnessingthemicrobiometoimproveimmunotherapeuticresponseinpancreaticcancer AT ryanmthomas prospectofharnessingthemicrobiometoimproveimmunotherapeuticresponseinpancreaticcancer |